Bayer is participating in the Alliance for Genomic Discovery (AGD) to gain access to genetic data linked to electronic health records (EHRs). This collaboration complements Bayer’s existing datasets by providing a valuable combination of genetic insights and clinical phenotypes, enabling deeper understanding and more contextualized use of genetic information.
A Diverse Cohort for Comprehensive Insights
A unique feature of the AGD is its inclusion of a substantial proportion of individuals with African-American ancestry, a population that is often underrepresented in genomic studies. Most current population and disease cohorts predominantly consist of individuals of Caucasian ancestry.
Access to diverse ancestry data is crucial for developing drugs that address the needs of all patients. Different ethnicities experience varying disease prevalence and responses to treatments. Understanding these differences at the molecular level allows Bayer to contribute to the development of more inclusive and effective medicines.
Advancing Disease Understanding
Through AGD, Bayer aims to improve disease understanding by exploring the molecular taxonomy of diseases. This approach benefits not only the pharmaceutical industry but also the broader research community. The data generated through AGD can be leveraged by researchers worldwide, fostering collaboration and innovation.
Personalizing Medicine for a Global Population
The era of “one-size-fits-all” treatments is over. Bayer is committed to making personalized medicine a reality by addressing the true diversity of the global population. By ensuring the right medicine is developed for the right patient, AGD supports the overarching goal of improving healthcare outcomes for all.
Through its participation in AGD, Bayer is taking a significant step toward creating a more inclusive and patient-centered future in medicine.
